#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Colorectal cancer metastatic Obesity Prostate cancer Crohn's disease Colorectal cancer Ovarian cancer Dementia Alzheimer's type Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    CDKL5 deficiency disorder Dermatomyositis Spina bifida Neurodermatitis Precursor T-lymphoblastic lymphoma/leukaemia recurrent Neurofibromatosis Becker's muscular dystrophy Still's disease Vernal keratoconjunctivitis HER2 mutant non-small cell lung cancer Bladder cancer Thyroid cancer metastatic Erdheim-Chester disease Epstein-Barr virus infection Gaucher's disease type III More trials…

    Learn about Rare Diseases

    Retinitis pigmentosa – Basic Information Alagille syndrome – Trials in Disease Rhabdomyosarcoma recurrent – Life with Disease Proteus syndrome Primary biliary cholangitis – Treatment Sarcoma – Basic Information Myelodysplastic syndrome with excess blasts – Diagnostics Breast angiosarcoma – Basic Information Systemic sclerosis pulmonary – Diagnostics Leiomyosarcoma metastatic – Treatment More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Ide397 Golcadomide CHLORMADINONE ACETATE Dazukibart Islatravir Masofaniten MB-HUCART19.1 ALN-961583 Evolocumab Bjt-778 METHYLPHENIDATE Casimersen Vib1116 ANX007 Pentoxifylline Oxybuprocaine HYDROXYCHLOROQUINE Spironolactone Sodium Chloride Lurasidone More therapies…

    Learn about Your Condition

    Breast cancer stage III Coma Medullary thyroid cancer Congenital pseudarthrosis Benign renal neoplasm Oedema Hyperparathyroidism primary Haemorrhage intracranial Foetal growth restriction Primary adrenal insufficiency Peripheral artery thrombosis Hepatitis D Vasospasm Essential hypertension Sinus rhythm More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Vaccine

  • A study to evaluate the safety and how pivekimab sunirine works in children with relapsed or refractory acute myeloid leukemia

    Recruiting

    1 1 1
    Investigated Diseases:
    • Acute myeloid leukaemia
    Investigated Drugs:
    • Pivekimab Sunirine
    Belgium Czechia France Hungary Italy Spain

  • A study of sacituzumab tirumotecan versus docetaxel, paclitaxel, or vinflunine for patients with pretreated advanced or metastatic bladder cancer

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • Vinflunine
    • Docetaxel
    • Paclitaxel
    Belgium France Germany Greece Italy The Netherlands +2

  • A Phase 3 Study of Elritercept Versus Epoetin Alfa in ESA‑Naïve Adults with Lower‑Risk Myelodysplastic Syndrome Requiring Red Blood Cell Transfusions

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • Elritercept
    • Epoetin Alfa
    Belgium Bulgaria France Germany Greece Hungary +8

  • One-Year Effectiveness Study of Guselkumab in Adults with Crohn’s Disease

    Recruiting

    3 1 1
    Investigated Diseases:
    • Crohn’s disease
    Investigated Drugs:
    • Guselkumab
    France

  • Phase 3 Study of INCB123667 versus investigator’s choice of chemotherapy drug combination in patients with platinum‑resistant ovarian cancer and cyclin E1 overexpression

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Ovarian cancer
    Investigated Drugs:
    • Topotecan Hydrochloride
    • INCB123667
    • Doxorubicin Hydrochloride
    Belgium France Germany Ireland Italy The Netherlands +2

  • Optimizing fludarabine phosphate exposure to improve event‑free survival in children and young adults with B‑cell acute lymphoblastic leukemia receiving CAR‑T therapy

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • Fludarabine Phosphate
    Germany The Netherlands Spain
Previous Page
1 … 28 29 30 31 32 … 1,645
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!